Vitamin D5
 | |
| Names | |
|---|---|
| IUPAC name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,4S)-4-ethyl-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-1-cyclohexanol | |
| Identifiers | |
71761-06-3  | |
| ChemSpider | 7826639  |
| |
| Jmol-3D images | Image |
| PubChem | 9547700 |
| |
| Properties | |
| C29H48O | |
| Molar mass | 412.69082 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| verify (what is: /?) | |
| Infobox references | |
Vitamin D5 is a form of vitamin D.
Analogues have been proposed for use as antitumor agents.[1][2][3]
See also
- 7-Dehydrositosterol
- Secalciferol
- Calcipotriene
References
- ↑ Mehta RG, Moriarty RM, Mehta RR et al. (February 1997). "Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5". J. Natl. Cancer Inst. 89 (3): 212–8. doi:10.1093/jnci/89.3.212. PMID 9017001.
- ↑ Murillo G, Mehta RG (October 2005). "Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5". J. Steroid Biochem. Mol. Biol. 97 (1-2): 129–36. doi:10.1016/j.jsbmb.2005.06.008. PMID 16051482.
- ↑ Mehta RG (October 2004). "Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5". Eur. J. Cancer 40 (15): 2331–7. doi:10.1016/j.ejca.2004.05.025. PMID 15454260.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||